| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Primary tumor growth was augmented in lymphedematous mice when B16 melanoma cells were subcutaneously injected. Expression of inflammatory cytokines as well as tumor-associated antigens in draining lymph nodes was significantly reduced in lymphedematous mice compared to wild-type mice. CD8+ T cells in draining LNs derived from lymphedematous mice bearing B16 melanoma also showed significantly decreased cytotoxic activity in vitro and in vivo. In summary, these findings suggest that lymphatic transport is essential in generating optimal tumor-specific immune responses. Moreover, early phase of leukocytoclastic vasculitis, the cutaneous and peritoneal reverse Arthus reactions, was attenuated in lymphedematous mice. Decreased Fc gamma receptor III expression on mast cells and macrophages may have resulted in reduced inflammation.
|
